Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VYGR
VYGR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VYGR News
Voyager Therapeutics Q1 Financial Results Analysis
3d ago
seekingalpha
FDA Grants Orphan Drug Designation to Neurocrine's NBIB-223
3d ago
seekingalpha
VY1706 Gene Therapy Shows Safety in Alzheimer's Study
Apr 27 2026
Newsfilter
Voyager Therapeutics CFO Resignation and New Appointment
Apr 21 2026
seekingalpha
Voyager Therapeutics Q4 Earnings Beat Expectations
Mar 09 2026
seekingalpha
UniQure's Gene Therapy Faces FDA Challenges
Mar 05 2026
CNBC
VectorY Receives FDA Clearance to Initiate PIONEER-ALS Trial for VTx-002
Dec 03 2025
Businesswire
J&J Stops Alzheimer's Study as Drug Proves Ineffective in Slowing Disease Progression
Nov 25 2025
Benzinga
Transition Bio and Voyager Team Up to Develop Small Molecules Aiming at TDP-43 for ALS and Frontotemporal Dementia
Nov 10 2025
Newsfilter
Analyst Highlights Momentum of Voyager Therapeutics' Alzheimer's Portfolio and ALPL NeuroShuttle Platform
Sep 15 2025
Benzinga
Three Biotech Stocks Rated 'Strong Buy' by Analysts with Potential Upside Exceeding 300%
Sep 05 2025
TipRanks
Voyager Therapeutics, Inc. (VYGR) Shares Insights at Citi's Biopharma Back to School Conference Transcript
Sep 02 2025
Newsfilter
Wedbush Maintains Outperform on Voyager Therapeutics, Lowers Price Target to $8
Aug 07 2025
Benzinga
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
Jul 16 2025
Newsfilter
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Jun 10 2025
Newsfilter
Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
May 31 2025
TipRanks
Show More News
